On this week's episode, we look at an increasingly full house of treatments which are being developed to join the club of autosomal dominant polycystic kidney disease medications. We look at what ADPKD is, who it affects, and what kinds of treatments on the horizon may be a diamond in the rough. Find out all about ADPKD in this fun podcast that raises spirits, suits a quest for knowledge, and doesn't bluff about this condition!

References:

Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019). Autosomal dominant polycystic kidney disease. The Lancet, 393(10174), 919-935. https://www.proquest.com/docview/2186986383?accountid=14690

Jdiaa, S. S., Mustafa, R. A., & Alan, S. L. (2025). Treatment of autosomal-dominant polycystic kidney disease. American Journal of Kidney Diseases, 85(4), 491-500. https://www.sciencedirect.com/science/article/pii/S0272638624010321

Koren, M. J., Chebib, M. (16 July, 2025). What's on the horizon for polycystic kidney disease (PKD)? On MedEvidence! Truth Behind the Data. [Podcast]. https://medevidence.com/whats-on-the-horizon-for-polycystic-kidney-disease-pkd

Chebib, F. T., & Torres, V. E. (2018). Recent advances in the management of autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology, 13(11), 1765-1776. https://pmc.ncbi.nlm.nih.gov/articles/PMC6237066/

Reiterová, J., & Tesař, V. (2022). Autosomal dominant polycystic kidney disease: from pathophysiology of cystogenesis to advances in the treatment. International journal of molecular sciences, 23(6), 3317. https://www.mdpi.com/1422-0067/23/6/3317

Kashyap, S., Zeidler, J. D., Chini, C. C., & Chini, E. N. (2020). Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease. Cellular signalling, 73, 109698. https://www.sciencedirect.com/science/article/abs/pii/S0898656820301753